Advances in human proteomics at high scale with the SOMAscan proteomics platform
Advances in human proteomics at high scale with the SOMAscan proteomics platform
复制标题
DOI：
10.1016/j.nbt.2011.11.016
复制
发表时间：
2012-06-15
影响因子：
5.4
通讯作者：
Williams, Stephen
中科院分区：
文献类型：
--
作者：
Gold, Larry;Walker, Jeffrey J.;Williams, Stephen
1997年，当我们还在Nexstar制药公司工作时，我们中的几个人打了一个蛋白质组学的赌注。我们当时认为，并将继续认为，蛋白质组学提供了识别疾病特异性生物标记物和改善医疗保健的机会。然而，询问蛋白质被证明是一个比询问核酸更困难的问题。因此，“组学”革命在很大程度上是由基因组学推动的。大规模蛋白质组学有望通过个性化的诊断、预防和治疗来改变医学。我们现在已经利用我们基于SOMAmer的新蛋白质组学平台，深入人类蛋白质组，对任何人类基质--血清、血浆、脑脊液、BAL以及组织提取物--中的1000多种蛋白质进行了量化。令人惊讶和令人高兴的消息是，我们已经将无偏见蛋白质生物标记物的发现作为一种常规和快速的练习。该平台对下游的影响是巨大的。
In 1997, while still working at NeXstar Pharmaceuticals, several of us made a proteomic bet. We thought then, and continue to think, that proteomics offers a chance to identify disease-specific biomarkers and improve healthcare. However, interrogating proteins turned out to be a much harder problem than interrogating nucleic acids. Consequently, the 'omics' revolution has been fueled largely by genomics. High-scale proteomics promises to transform medicine with personalized diagnostics, prevention, and treatment. We have now reached into the human proteome to quantify more than 1000 proteins in any human matrix - serum, plasma, CSF, BAL, and also tissue extracts - with our new SOMAmer-based proteomics platform. The surprising and pleasant news is that we have made unbiased protein biomarker discovery a routine and fast exercise. The downstream implications of the platform are substantial.